M Ladetto

Summary

Affiliation: University of Turin
Country: Italy

Publications

  1. ncbi Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients
    M Ladetto
    Divisione Universitaria di Ematologia Azienda Opedaliera S Giovanni Battista Torino, Italy
    Med Oncol 17:203-10. 2000
  2. ncbi High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity
    C Tarella
    Dipartimento di Medicina e Oncologia Sperimentale, Ospedaliera S Giovanni Battista di Torino, Italy
    Leukemia 15:256-63. 2001
  3. doi Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall surviva
    Marco Ladetto
    Divisione Universitaria di Ematologia, Cattedra di Ematologia, Torino, Italy
    Blood 111:4004-13. 2008
  4. pmc Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes
    Simone Ferrero
    Division of Hematology, Department of Experimental Medicine and Oncology, University of Turin, Italy
    Haematologica 97:849-53. 2012
  5. ncbi Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome
    Marco Ladetto
    Dipartimento di Medicina ed Oncologia Sperimentale, Servizio di Epidemiologia dei Tumori e Biostatistica, Centro di Ricerca in Medicina Sperimentale, Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
    Blood 105:4784-91. 2005
  6. ncbi Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial
    M Ladetto
    Divisione Universitaria di Ematologia, Cattedra di Ematologia, Torino, Italy
    Leukemia 20:1840-7. 2006
  7. ncbi Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma
    Marco Ladetto
    Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, Torino, Italy
    Biol Blood Marrow Transplant 12:1270-6. 2006
  8. ncbi Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders
    Marco Ladetto
    Cattedra di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Via Genova 3, 10126 Turin, Italy
    Blood 103:4644-9. 2004
  9. ncbi Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone
    Marco Ladetto
    Divisione di Ematologia Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, A O San Giovanni Battista della Citta di Torino, Torino, Italy
    Exp Hematol 31:784-8. 2003
  10. doi Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma
    Marco Ladetto
    Cattedra di Ematologia, Via Genova 3, 10126 Torino, Italy
    J Clin Oncol 28:2077-84. 2010

Detail Information

Publications28

  1. ncbi Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients
    M Ladetto
    Divisione Universitaria di Ematologia Azienda Opedaliera S Giovanni Battista Torino, Italy
    Med Oncol 17:203-10. 2000
    ....
  2. ncbi High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity
    C Tarella
    Dipartimento di Medicina e Oncologia Sperimentale, Ospedaliera S Giovanni Battista di Torino, Italy
    Leukemia 15:256-63. 2001
    ..It implies good tolerability and reversible cardiotoxicity and it may have contributed to the good long-term outcome observed in this series of patients...
  3. doi Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall surviva
    Marco Ladetto
    Divisione Universitaria di Ematologia, Cattedra di Ematologia, Torino, Italy
    Blood 111:4004-13. 2008
    ..This trial was registered at www.clinicaltrials.gov as no. NCT00435955...
  4. pmc Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes
    Simone Ferrero
    Division of Hematology, Department of Experimental Medicine and Oncology, University of Turin, Italy
    Haematologica 97:849-53. 2012
    ..Early B-lymphocyte precursors of multiple myeloma are known to exist and might be susceptible to antigenic drive...
  5. ncbi Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome
    Marco Ladetto
    Dipartimento di Medicina ed Oncologia Sperimentale, Servizio di Epidemiologia dei Tumori e Biostatistica, Centro di Ricerca in Medicina Sperimentale, Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
    Blood 105:4784-91. 2005
    ..Future studies will assess COX-2 involvement in other hematologic tumors and its potential use as a therapeutic or chemo-preventive target in onco-hematology...
  6. ncbi Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial
    M Ladetto
    Divisione Universitaria di Ematologia, Cattedra di Ematologia, Torino, Italy
    Leukemia 20:1840-7. 2006
    ..As the HDS schedule can be easily supplemented with Rituximab, it is one of the best options for random comparison with Rituximab-supplemented conventional chemotherapy...
  7. ncbi Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma
    Marco Ladetto
    Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, Torino, Italy
    Biol Blood Marrow Transplant 12:1270-6. 2006
    ..Our results indicate that rituximab is active against residual MCL cells and suggest that molecularly tailored maintenance therapy needs to be investigated in clinical trials...
  8. ncbi Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders
    Marco Ladetto
    Cattedra di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Via Genova 3, 10126 Turin, Italy
    Blood 103:4644-9. 2004
    ....
  9. ncbi Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone
    Marco Ladetto
    Divisione di Ematologia Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, A O San Giovanni Battista della Citta di Torino, Torino, Italy
    Exp Hematol 31:784-8. 2003
    ....
  10. doi Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma
    Marco Ladetto
    Cattedra di Ematologia, Via Genova 3, 10126 Torino, Italy
    J Clin Oncol 28:2077-84. 2010
    ..Moreover, the major reduction in tumor load recorded by RQ-PCR after VTD suggests that unprecedented levels of tumor cell reduction can be achieved in MM thanks to the new nonchemotherapeutic drugs...
  11. ncbi PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy
    Marco Ladetto
    Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale Universita di Torino, Italy
    J Clin Oncol 21:1398-403. 2003
    ....
  12. ncbi High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
    Marco Ladetto
    Divisione Universitaria di Ematologia, Cattedra di Ematologia, Ospedale S Giovanni Vecchio antica sede, Torino, Italy
    Blood 100:1559-65. 2002
    ....
  13. ncbi Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests
    Marco Ladetto
    Divisione Universitaria di Ematologia, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Exp Hematol 30:529-36. 2002
    ..In this study, we used a validated real-time polymerase chain reaction (PCR) strategy to evaluate LTC of BM and PBPC samples obtained from MM patients...
  14. ncbi Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting
    M Ladetto
    Divisione Universitaria di Ematologia Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Leuk Lymphoma 40:679-82. 2001
    ..However, the prolonged remission duration observed in this patient suggests that achieving PCR-negativity may also be of benefit for MCL patients...
  15. ncbi A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients
    M Ladetto
    Divisione Universitaria di Ematologia, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Exp Hematol 29:183-93. 2001
    ..In this study we evaluated whether there is a relationship between tumor burden of stem cell harvests and successful clearance of PCR-detectable disease following ex vivo manipulation...
  16. ncbi Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations
    Marco Ladetto
    Divisione di Ematologia Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino A O San Giovanni Battista della Citta di Torino, Torino, Italy
    Exp Hematol 34:1680-6. 2006
    ..To address these issues we prospectively monitored a panel of NLABR-positive LFS...
  17. ncbi Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma
    M Ladetto
    Divisione Universitaria di Ematologia-Dipartimento di Medicina ed Oncologia Sperimentale, , Torino, Italy
    Leukemia 15:1941-9. 2001
    ..In pre-treated patients this treatment also showed promising results, although the risk of severe infections needs to be considered...
  18. ncbi Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF
    I Ricca
    Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino and A O S Giovanni Battista, Torino, Italy
    Leukemia 19:644-51. 2005
    ....
  19. ncbi Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italian
    C Tarella
    Dip Medicina Oncologia Sperimentale, Divisione Universitaria di Ematologia, Torino, Italy
    Leukemia 21:1802-11. 2007
    ..Thus, life expectancy of younger patients with aaIPI 2-3 DLB-CL is improved with the early administration of rituximab-supplemented intensive chemotherapy compared with the poor outcome following conventional chemotherapy...
  20. ncbi Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells
    P Corradini
    Dipartimento di Medicina ed Oncologia Sperimentale, Azienda Ospedaliera San Giovanni Battista Divisione Universitaria di Ematologia, Torino, Italy
    J Clin Oncol 17:208-15. 1999
    ..To describe molecular monitoring of minimal residual disease in patients with myeloma who have achieved complete remission (CR) after autologous or allogeneic transplantation of hematopoietic cells...
  21. ncbi Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients
    I Ricca
    Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Leukemia 21:697-705. 2007
    ..In conclusion, TRF-L can be helpful to refine prognostication of B-CLL patients, particularly those with a VH-unmutated immunoglobulin sequence...
  22. doi Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status
    M Ruella
    Dipartimento di Medicina ed Oncologia Sperimentale, Divisione di Ematologia, Universita di Torino, Torino, Italy
    Bone Marrow Transplant 45:505-12. 2010
    ..0005); following HSCT, BM TL (median 7380 bp) was identical to that of the graft (P=NS). We conclude that grafted cells have a major role in determining TL after HSCT...
  23. ncbi Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
    M Ladetto
    Division of Hematology, A O Azienda Ospedaliera Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy
    Leukemia 28:1299-307. 2014
    ..We conclude that NGS is an effective tool for MRD monitoring in ALL, MCL and MM. Prospective comparative analysis of unselected cases is required to validate the clinical impact of NGS-based MRD assessment. ..
  24. pmc Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells
    S Lamorte
    Department of Internal Medicine, Research Center for Experimental Medicine CeRMS, University of Torino, Torino, Italy
    Leukemia 26:1081-90. 2012
    ..These results suggest that syndecan-1 may contribute to the highly angiogenic phenotype of MMECs by promoting EC proliferation, survival and modulating VEGF-VEGFR-2 signalling...
  25. doi IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells
    M Coscia
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliero Universitaria San Giovanni Battista di Torino, Torino, Italy
    Leukemia 25:828-37. 2011
    ..This vulnerability of UM CLL B cells can be exploited as a selective target of therapeutic interventions...
  26. ncbi Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma
    A Trojan
    Multidisciplinary Oncology Centre, Centre Hospitalier Universitaire Vaudois, CHUV, Lausanne, Switzerland
    Swiss Med Wkly 136:400-3. 2006
    ..However, patients with COX-2 positive tumours experienced a significantly shorter time to progression (17 vs 30 months, p = 0.037). In summary, COX-2 is frequently expressed in MM and correlates with shorter progression-free survival...
  27. ncbi Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation
    C Voena
    Laboratorio Ematologia Molecolare, Istituto Scientifico HS Raffaele, Milano, Italy
    Bone Marrow Transplant 32:791-3. 2003
    ..These data suggest that real-time molecular follow-up can be used to monitor the GVM effect and that it can be employed in the clinical setting to tailor post transplant immunomodulation...
  28. ncbi BRAF gene is not mutated in plasma cell leukemia and multiple myeloma
    L Bonello
    Leukemia 17:2238-40. 2003